{"filings":[{"id":1471447,"accession_number":"0001493152-26-032155","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2026-07-06T20:05:39+00:00","items":["1.01","5.02","5.07","9.01"],"status":"ready","headline":"Oragenics appoints John Spencer as CFO; shareholders authorize reverse stock split","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Spencer appointed CFO effective July 1, 2026; base salary $200,000, option award of $25,000.","Shareholders re-elected all six directors: Pope, Telling, Koski, Dunton, Gandolfo, Giordano.","Non-binding advisory vote on executive compensation passed (806,898 for, 478,522 against).","Shareholders authorized reverse stock split at ratio between 1:2 and 1:50, within one year.","Ratification of Cherry Bekaert LLP as auditors for 2026 passed (1,887,381 for, 184,883 against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":509156,"accession_number":"0001493152-26-024363","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2026-05-19T12:38:18+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Oragenics dosed first patient in Phase IIa concussion trial; signs LOI for CNS device","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase IIa trial of ONP-002 in Australia active; first patient dosed at Mackay Base Hospital March 2026.","Signed LOI to license a complementary CNS medical device; expands addressable indication set beyond ONP-002.","Cash balance $6.1M as of Q1 2026; R&D expenses $0.6M (up 89% YoY); G&A $1.6M (down 4% YoY).","Targets Type C meeting with FDA in Q2 2026, IND submission by end of 2026, Phase IIa data readout in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91680,"accession_number":"0001493152-26-021627","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oragenics signs LOI to license CardioDialysis from Sigyn Therapeutics for TBI","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["LOI grants Oragenics exclusive license for CardioDialysis blood purification tech in TBI and chronic neurodegenerative diseases.","Consideration: 3,250,000 shares of preferred stock convertible 1:1 to common, plus 3% royalty for 6 years post-FDA clearance.","Target closing within 90 days; Sigyn exclusivity during that period; subject to due diligence, board approvals, and NYSE American rules.","Oragenics also advancing ONP-002 (Phase IIa intranasal neurosteroid); combined approach targets TBI inflammation on both sides of BBB.","No FDA-approved pharmacological treatment for concussion/mTBI; 69 million brain injuries occur annually worldwide."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91679,"accession_number":"0001493152-26-016294","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oragenics dosed first patient in Phase IIa trial of ONP-002 for mild traumatic brain injury","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed at Mackay Hospital (Australia) days after site activation on March 31, 2026.","Phase IIa is randomized, placebo-controlled, targeting 40 patients; dosing within 12 hours of concussion.","Additional sites (Alfred Hospital, Royal Adelaide Hospital) expected to activate in Q2 2026.","Company plans to submit IND to FDA in Q4 2026 for U.S. Phase IIb trials.","Phase 1 safety data showed zero serious adverse events across all dose levels."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101917,"accession_number":"0001493152-26-014128","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["5.08","9.01"],"status":"ready","headline":"Oragenics sets 2025 annual meeting for June 29, 2026; new deadline for shareholder proposals May 1, 2026","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board scheduled 2025 Annual Meeting for June 29, 2026, more than 30 days from 2024 meeting anniversary.","Shareholder proposals under Rule 14a-8 must be received by May 1, 2026.","Proposals should be delivered to Oragenics' principal executive office in Lakewood Ranch, FL."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101916,"accession_number":"0001493152-26-009682","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oragenics gets HREC approval, starts Phase IIa site activation for ONP-002 in Australia; explores CNS asset acquisition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received final HREC approval in Australia for Phase IIa trial of ONP-002 for concussion/mTBI.","Completed first site initiation visit (SIV) for Phase IIa trial; two more sites in final RGO review.","Phase IIa trial of 40 patients; first dose within 12 hours of injury; data readout expected before year-end 2026.","Exploring discussions with third parties for potential acquisition of CNS assets focusing on brain health/recovery.","No definitive agreements reached; platform expansion independent of Receptor.AI partnership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101915,"accession_number":"0001493152-26-003237","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2026-01-22T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Oragenics extends ATM equity distribution agreement with Dawson James","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On January 22, 2026, Oragenics amended its at-the-market sales agreement with Dawson James Securities.","The amendment extends the agreement term until all shares are sold or the shelf registration expires.","No other terms of the original October 11, 2024 agreement were modified.","The ATM facility allows the company to sell common stock from time to time on NYSE American."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101914,"accession_number":"0001493152-26-002759","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2026-01-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Oragenics CEO presents at Sequire Investor Summit; filing lacks specific financial data","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["CEO presented at Sequire Investor Summit on January 20, 2026, using a new corporate presentation.","Presentation filed as Exhibit 99.1 and will be hosted on the company website under 'Presentations'.","No specific financial results, guidance, or operational milestones were detailed in the filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118252,"accession_number":"0001493152-25-027745","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Oragenics board boosts CEO salary 5% to $341,250, awards bonus and options","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO Janet Huffman base salary increased 5% from $325,000 to $341,250 effective Jan 1, 2026.","CEO awarded $110,500 bonus for FY2025 performance against goals.","CEO granted options for 250,000 shares at $0.93, vesting over 3 years.","Each non-employee director received immediately vested options for 125,000 shares at $0.93.","Director Giordano received onboarding option award worth $30,000 at prior closing price (vested immediately)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118251,"accession_number":"0001493152-25-021749","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oragenics regains NYSE compliance, raises $16.5M, partners with Receptor.AI, advances Phase IIa trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Regained NYSE American compliance on Oct 20, 2025, resolving equity deficiency and removing below-compliance indicator.","Completed $16.5M gross capital raise via Series H Convertible Preferred Stock in July 2025; net proceeds ~$15.2M.","Eliminated $3M note payable and restored stockholder equity above the $6M NYSE threshold.","Formed strategic collaboration with Receptor.AI to use AI-driven discovery for pipeline beyond concussion.","Anticipates Phase IIa trial initiation for ONP-002 in Q4 2025/Q1 2026 in Australia, with U.S. Phase IIb planning underway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118250,"accession_number":"0001493152-25-018725","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["1.01","3.01","7.01","9.01"],"status":"ready","headline":"Oragenics settles Ladenburg dispute for $700K; regains NYSE American compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Paid $700K to Ladenburg Thalmann to settle $2.5M fee dispute; mutual release and arbitration dismissal.","Regained compliance with NYSE American Section 1003(a) as stockholders' equity exceeds $6M as of Oct 18, 2025.","Compliance restored after $16.5M Series H Preferred Stock offering in July 2025; .BC indicator to be removed.","Company now focusing on advancing ONP-002 concussion treatment into Phase IIa trials in Australia and planning U.S. Phase IIb."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134693,"accession_number":"0001493152-25-012562","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Oragenics appoints Natasha Giordano to board of directors effective Sept 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Natasha Giordano appointed to Oragenics Board effective September 1, 2025.","Ms. Giordano brings experience from PLx Pharma (CEO), Matinas BioPharma board, and HCA.","She will receive annual base director fee of $45,000, pro-rated, and $3,750/month for Sept-Dec 2025.","She has agreed to stand for re-election at next annual meeting of shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134692,"accession_number":"0001641172-25-022908","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oragenics raises $16.5M, advances ONP-002 Phase IIa concussion trial for Q3 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised $16.5M via Series H Preferred Stock and Warrants; net proceeds ~$15.2M after fees.","HREC approval secured in Australia; Southern Star Research appointed CRO; Sterling Pharma Solutions for cGMP manufacturing.","Phase IIa trial initiation anticipated Q3 2025; IND submission for Phase IIb expected Q3-Q4 2025.","Six months ended June 30, 2025: R&D expenses down 50%, G&A costs down 8%, net losses down 6% YoY.","No FDA-approved pharmacological treatment currently exists for concussion; market opportunity $8.9B by 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134691,"accession_number":"0001641172-25-017575","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2025-07-02T23:59:59+00:00","items":["1.01","3.03","5.03","8.01","9.01"],"status":"ready","headline":"Oragenics closes $16.5M public offering of Series H Preferred Stock and Warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 660,000 shares of Series H Convertible Preferred Stock at $25/unit with warrants to buy 660,000 additional shares.","Preferred Stock converts to common at $2.50 per share; warrants exercise at $25/share for 5 years.","Gross proceeds ~$16.5M; net ~$15M after fees; potential additional $16.5M if all warrants exercised.","Net proceeds to fund ONP-002 concussion trials, repay $3M bridge note, and general corporate purposes.","Preferred Stock carries 9% cumulative dividend payable in common stock; no voting rights except as law requires."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151601,"accession_number":"0001641172-25-012596","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Oragenics approves 1-for-30 reverse stock split to meet NYSE American listing standards","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-30 ratio; effective 12:01 a.m. ET on June 3, 2025.","Outstanding shares reduced from ~21.5M to ~715,843 post-split; fractional shares rounded up.","Split intended to boost share price and meet NYSE American continued listing standards.","Trading symbol remains OGEN; new CUSIP 684023 609."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151600,"accession_number":"0001641172-25-011774","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Oragenics furnishes Neurotrauma Medicine presentation; no specifics disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation on Neurotrauma Medicine provided for Scientific Advisory Board webinar on May 20, 2025.","No financial or operational data included in the filing or exhibit.","Presentation posted under 'Presentations' section of oragenics.com."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151599,"accession_number":"0001641172-25-008389","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2025-05-02T23:59:59+00:00","items":["1.01","5.02","5.07","9.01"],"status":"ready","headline":"Oragenics appoints Janet Huffman as permanent CEO; shareholders authorize reverse stock split up to 1:50","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Janet Huffman, previously CFO and Interim CEO, appointed permanent CEO effective May 2, 2025 under one-year agreement.","Base salary $325,000, bonus target up to 50% of base, severance includes 6 months salary and change-in-control provisions.","Shareholders authorized a reverse stock split of common stock between 1:5 and 1:50 ratio, Board to determine exact ratio.","Authorized increase in authorized shares to 350M contingent on reverse split; 2021 Equity Incentive Plan shares increased to 3,166,667.","All five directors re-elected: Pope, Telling, Koski, Dunton, Gandolfo. Auditor Cherry Bekaert ratified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151598,"accession_number":"0001641172-25-003334","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oragenics submits Phase II concussion trial protocol to NZ ethics committee","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Submitted clinical trial protocol to Health and Disability Ethics Committee (HDEC) in New Zealand for Phase II trial of ONP-002 for mild traumatic brain injury.","Pending HDEC approval, expects to initiate patient enrollment at Christchurch Hospital, one of the busiest emergency departments in Australasia.","ONP-002 is an intranasal neurosteroid therapy; no approved pharmaceutical exists for concussion, an unmet medical need.","Phase I study showed safety and tolerability; Phase II will evaluate efficacy in mTBI patients.","Company plans to expand global clinical footprint with sites in both Australia and New Zealand."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170450,"accession_number":"0001641172-25-000855","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oragenics Q1 update: $5M raised, ONP-002 Phase IIa trial advances","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised ~$2.6M via ATM equity and ~$2.25M via non-dilutive debt; submitted DoD grant for concussion program.","Submitted Investigator's Brochure for Phase IIa trial in Australia; trial listed on ClinicalTrials.gov; awaiting HREC approval.","Partnered with BRAINBox Solutions to combine intranasal ONP-002 with diagnostic biomarkers for personalized concussion care.","Upcoming milestones: HREC approval and first patient enrollment in Q2 2025; Phase IIa enrollment completion by Q4 2025.","Simplified capital structure by converting all preferred shares to common; annual meeting set for May 2, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170449,"accession_number":"0001493152-25-009335","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oragenics submits Investigator's Brochure for Phase II trial of ONP-002 in Australia","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase II trial of intranasal neurosteroid ONP-002 for mild traumatic brain injury (mTBI); up to 40 participants enrolled across two arms.","Trial is randomized, double-blind, placebo-controlled; nine doses over five days, first dose within 12 hours of injury.","Prior Phase I confirmed safety and tolerability at multiple intranasal doses in healthy adults.","No FDA-approved drug therapies currently exist for concussion, an unmet medical need.","Interim CEO Janet Huffman anticipates final regulatory approvals in coming weeks to initiate trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170448,"accession_number":"0001493152-25-007182","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["5.08","9.01"],"status":"ready","headline":"Oragenics sets 2024 Annual Meeting for May 16, 2025; shareholder proposal deadline March 14","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board scheduled 2024 Annual Meeting for May 16, 2025, over 30 days later than 2023 meeting anniversary.","Shareholder proposals under Rule 14a-8 must be received by March 14, 2025.","Proposals to be sent to Oragenics principal office: 1990 Main Street, Suite 750, Sarasota, FL 34236.","Record date and location will be stated in the proxy statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170447,"accession_number":"0001493152-25-004946","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oragenics CMO Dr. James Kelly to speak at 12th Annual Brain Health Summit on Feb 8, 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Dr. James P. Kelly, Oragenics CMO, will be a featured panelist at the 12th Annual Brain Health Summit on Feb 8, 2025 in New Orleans.","Summit focuses on awareness, prevention, and care for athletic concussions and traumatic brain injury (TBI) treatment.","Oragenics is developing ONP-002, an intranasal neurosteroid for concussion treatment, which Dr. Kelly will discuss.","Event is hosted by sports agent Leigh Steinberg during Super Bowl celebrations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170446,"accession_number":"0001493152-25-002928","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2025-01-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oragenics appoints CFO Janet Huffman as interim CEO; provides ONP-002 Phase II timeline","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Janet Huffman named interim CEO, retaining CFO role; board expresses confidence in her leadership.","Company raised $4M in September 2024; progress includes improved ONP-002 formulation and device prototyping.","Phase II trial in Australia: first patient dosing targeted by end of Q1 2025 or early Q2 2025.","IND package for U.S. Phase IIb clinical trial targeted for Q3 2025.","Spray-dry campaign completed to ensure sufficient drug-device units for upcoming trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170445,"accession_number":"0001493152-25-002751","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2025-01-17T23:59:59+00:00","items":["1.01","5.02","8.01","9.01"],"status":"ready","headline":"Oragenics names CFO Janet Huffman Interim CEO at $275K salary; director resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Janet Huffman appointed Interim CEO effective Jan 16, 2025; salary increased 10% to $275,000 with $75,000 cash bonus.","Director Bruce Cassidy resigned Jan 15, 2025 to pursue other opportunities; no disagreement with Company.","All pre-funded warrants from September 2024 offering exercised; 13,709,805 common shares outstanding as of Jan 16, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187436,"accession_number":"0001493152-24-050216","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["5.02","5.07","8.01","9.01"],"status":"ready","headline":"Oragenics appoints CFO Janet Huffman as Interim CEO; Preferred conversion cancels $2.35M liquidation preference","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["J. Michael Redmond terminated as Interim CEO/President effective Dec 16, 2024; CFO Janet Huffman appointed as new Interim CEO and President.","Shareholders approved increasing 2021 Equity Incentive Plan by 2M shares to total 3,166,667 shares.","All remaining Series A (5,417,000) and Series B (4,050,000) preferred shares converted to ~22,000 common shares, eliminating $2.35M liquidation preference.","Directors re-elected: Charles Pope, Frederick Telling, Alan Dunton, Robert Koski, John Gandolfo, Bruce Cassidy.","Advisory vote on executive compensation passed with 1,931,906 for vs 365,871 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187435,"accession_number":"0001493152-24-048190","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2024-11-29T23:59:59+00:00","items":["1.02","9.01"],"status":"ready","headline":"Oragenics notifies President J. Michael Redmond of non-renewal of employment agreement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Company gave non-renewal notice on Nov 26, 2024, for Employment Agreement dated Dec 28, 2023.","Agreement's initial one-year term expires; employment terminates at end of that term.","Certain provisions survive the expiration per the agreement's terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187434,"accession_number":"0001493152-24-041500","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2024-10-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Oragenics President to present at Centurion One Capital Bahamas Summit on Oct 22, 2024","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["President Michael Redmond will present and host a Q&A at the summit on October 22, 2024 at 1:20 p.m. ET.","The conference is held at Rosewood Baha Mar Hotel in Nassau, Bahamas on October 22-23, 2024.","Oragenics focuses on nasal delivery for neurology and infectious diseases, including mTBI and NPC treatments.","No financial results or material corporate developments disclosed in the press release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187433,"accession_number":"0001493152-24-041255","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2024-10-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Oragenics files 8-K to furnish investor presentation; no specifics provided in filing text.","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company filed Form 8-K under Item 7.01 for Regulation FD disclosure of a presentation.","Exhibit 99.1 (presentation) referenced but not included in the provided text; content unknown.","Presentation intended for use with potential investors and available on company website.","No financial or operational updates disclosed in the filing itself."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187432,"accession_number":"0001493152-24-040974","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Oragenics enters $10M ATM stock offering agreement with Dawson James","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["May sell up to $10M common shares at-the-market through Dawson James Securities.","Sales agent commission of 3.0% of gross proceeds; reimbursement up to $30,000.","Net proceeds to fund ONP-002 development and general corporate purposes.","Shares sold on NYSE American; no obligation to sell any shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187431,"accession_number":"0001493152-24-040523","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2024-10-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oragenics updates on concussion drug ONP-002 progress; Phase II trial preparation advanced","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ONP-002 cleared FDA cardiotoxicity and genotoxicity tests; spray-dry formulation completed with 4-fold drug increase per dose.","$4.45M public offering closed Sep 2024; total $6M+ raised in 2024 to fund Phase II trial.","Phase II trial planned later 2024, first in Australia then U.S.; evaluates efficacy on symptom reduction and functional recovery.","Appointed Dr. James Kelly as CMO and Dr. William Peacock as CCO in 2024 for clinical oversight.","Partnership with Avance Clinical in May 2024; Australian Regulatory Submission Brochure targeted Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203956,"accession_number":"0001493152-24-037602","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["5.02","5.08","9.01"],"status":"ready","headline":"Oragenics awards stock options to executives; reschedules annual meeting to Dec 11, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Compensation Committee approved immediate-vesting stock options: 100k shares to President Redmond, 80k to CFO Huffman.","Options granted under 2021 Equity Incentive Plan; vest immediately upon grant.","2023 Annual Meeting rescheduled to December 11, 2024; shareholder proposals due October 20, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203955,"accession_number":"0001493152-24-035166","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2024-09-05T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Oragenics raises $4.45M in public offering; sold shares and pre-funded warrants at $0.55","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$4.45M from offering of 3,078,378 shares and 5,028,206 pre-funded warrants.","Net proceeds ~$3.79M after placement agent fees (7%) and estimated expenses.","Proceeds to fund ONP-002 development for mild traumatic brain injury and general working capital.","Post-offering shares outstanding: 8,659,071 common shares plus 5,028,206 pre-funded warrants.","Placement agent Dawson James receives 7% cash fee and warrants for 5% of securities sold at 125% of offering price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203954,"accession_number":"0001493152-24-033383","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2024-08-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oragenics completes spray-dry manufacturing of ONP-002 for Phase IIa concussion trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ONP-002 produced as spray-dried nanoparticle powder and filled in Oragenics' breath-propelled intranasal device.","Phase IIa trial to enroll 40 concussed patients (1:1 placebo/ONP-002), dosed twice daily for 5 days starting within 8 hours of injury in ED.","Trial will be conducted in Australia; patient-reported outcomes and blood biomarkers included in evaluation.","No approved pharmaceutical treatment for concussion; ONP-002 is a novel neurosteroid designed as first-in-class therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203953,"accession_number":"0001493152-24-032831","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2024-08-16T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"Oragenics receives NYSE delisting notice for equity shortfall; ONP-002 Phase 2 trial planned Q4 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NYSE American notified Oragenics it is not in compliance with Section 1003(a)(i) (stockholders' equity <$2M); compliance plan approved, deadline Oct 18, 2025.","ONP-002 cleared FDA-required cardiotoxicity and genotoxicity tests; Phase 2 trial expected to start Q4 2024 in Australia.","Improved intranasal formulation increases ONP-002 per dose by 4X; automated device prototype for use in acute concussion completed.","Closed public offering raising ~$1.1M to fund ONP-002 development and corporate needs.","Appointed Dr. Peacock as Chief Clinical Officer and Dr. Kelly as Chief Medical Officer for Phase 2 trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203952,"accession_number":"0001493152-24-031898","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oragenics reports ONP-002 stable across wide temperature range, eliminating cold storage needs for concussion drug","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ONP-002 shows >99% purity after 3-month stability testing at -20°C to 104°C.","Drug-device combination designed for acute field-delivery without cumbersome cold chain logistics.","Phase II clinical trial batch synthesis completed; no FDA-approved pharmaceutical treatment currently exists for concussion.","Estimated 69 million concussions annually worldwide; drug targets intranasal delivery within minutes of injury."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203951,"accession_number":"0001493152-24-031163","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oragenics: concussion drug ONP-002 shows no genotoxicity in animal study; Phase II planned","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ONP-002 completed in vivo micronucleus assay; no evidence of genetic mutations or DNA damage across low, medium, high doses.","Study conducted under GLP conditions with VivoPharm; supports safety for planned Phase II clinical trial for concussion.","Company previously reported safety margin in two-species tox and cardiac safety (GLP hERG); now genotoxicity cleared.","Concussion affects ~69M annually globally; post-concussion symptoms cause long-term disability in up to 20% of patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203950,"accession_number":"0001493152-24-030682","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oragenics' concussion drug ONP-002 passes FDA cardiotoxicity test, Phase II planned","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ONP-002 showed no cardiotoxicity in GLP hERG study conducted by Charles River Laboratories.","Inhibitory concentration >10 µM; large cardiac safety margin based on Phase I plasma levels.","Phase II trial planning underway to evaluate ONP-002 in concussed patients.","Concussion market estimated at 69M cases globally; annual US healthcare cost for TBIs exceeds $40.6B.","ONP-002 is an intranasal neurosteroid new chemical entity targeting mild traumatic brain injury."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203949,"accession_number":"0001493152-24-028687","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2024-07-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oragenics postpones 2023 Annual Meeting previously set for Aug 26, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board postponed the Aug 26, 2024 meeting; new date to be announced.","Shareholder proposal deadlines for the 2023 proxy statement will be updated.","No reason for delay given; meeting is for fiscal 2023 and was already late.","Company trades on NYSE American under ticker OGEN."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203948,"accession_number":"0001493152-24-026724","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2024-07-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oragenics develops improved intranasal formulation for concussion drug ONP-002","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["New formulation of ONP-002 designed to enhance brain uptake via nasal cavity, potentially reducing concussion symptoms.","Oragenics reports increased final dose levels and improved intranasal adhesion for longer absorption times.","Phase II study in concussed patients being planned to assess safety, feasibility, and effectiveness using blood biomarkers.","Concussion is a serious unmet need with 69 million cases annually worldwide; leads to long-term disability in up to 20%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220600,"accession_number":"0001493152-24-025281","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Oragenics closes public offering of 1.1M shares at $1.00, raising $1.1M gross","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 1,100,000 common shares at $1.00 per share closed on June 26, 2024.","Gross proceeds of approximately $1.1M; net proceeds to fund ONP-002 development and working capital.","Placement agent Dawson James receives 7% cash fee and five-year warrants at 125% of offering price.","Shares sold under effective S-3 shelf registration statement filed January 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220599,"accession_number":"0001493152-24-024423","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Oragenics gains NYSE American approval of compliance plan; listed with 'BC' indicator through Oct 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NYSE American accepted Oragenics' plan to regain compliance with continued listing standards by October 18, 2025.","Company must make progress and is subject to quarterly monitoring; if not, delisting proceedings may initiate after Oct 18, 2025.","During plan period, stock trades under symbol OGEN with '.BC' indicator."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220598,"accession_number":"0001493152-24-021103","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Oragenics reschedules 2023 Annual Meeting to August 26, 2024; sets June 21 deadline for shareholder proposals","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual Meeting rescheduled from July 15, 2024 to August 26, 2024.","Shareholder proposals under Rule 14a-8 must be received by June 21, 2024.","Submit proposals to Oragenics, Inc., Attn: Corporate Secretary, Sarasota, FL 34236."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220597,"accession_number":"0001493152-24-020964","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oragenics appoints Dr. William Peacock as Chief Clinical Officer for Phase II concussion trial","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Dr. William 'Frank' Peacock as Chief Clinical Officer effective May 22, 2024.","Dr. Peacock will oversee upcoming Phase II trial of ONP-002 for concussion in emergency departments.","Dr. Peacock is Vice Chair for Emergency Medicine Research at Baylor College of Medicine.","ONP-002, a new chemical entity delivered intranasally, showed safety in Phase I; Phase II planned.","Concussion is an unmet need with ~69M cases annually; post-concussion syndrome occurs in up to 20% of patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220596,"accession_number":"0001493152-24-020362","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oragenics to host Neurotrauma Medicine webinar; will present ONP-002 mTBI update","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Webinar scheduled for May 20, 2024, at 12:00 PM ET.","Lead drug candidate ONP-002, a neurosteroid for mild TBI, to be discussed.","Company to review preclinical/Phase I data and provide details on upcoming Phase II trial in acute/emergency settings.","No financial results or regulatory milestones announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220595,"accession_number":"0001493152-24-020128","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oragenics preparing Phase II trial for concussion drug ONP-002; secures CRO, optimizes formulation","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["ONP-002 intranasal neurosteroid for mild TBI (concussion) advances to Phase II after positive Phase I safety.","Partnering with Avance Clinical for Phase IIa at level one trauma centers in Australia.","Formulation optimized to increase active compound percentage and target brain absorption within minutes.","Estimated 69 million concussion cases globally annually; up to 20% develop post-concussion syndrome.","Adequate intranasal device supply secured for upcoming trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220594,"accession_number":"0001493152-24-018025","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oragenics partners with Avance Clinical for Phase II concussion trial of ONP-002 in Australia","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase II trial to evaluate ONP-002 for mild traumatic brain injury (concussion) delivered intranasally.","Phase I trial completed under Avance Clinical showed ONP-002 safe and well-tolerated.","Avance Clinical, a CRO with 20+ years experience, will manage the trial in Australia.","Oragenics President cites confident execution; CMO highlights Australia's head injury expertise.","Worldwide annual concussions estimated at 69 million; post-concussion syndrome occurs in up to 20%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220593,"accession_number":"0001493152-24-015404","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2024-04-22T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"Oragenics receives NYSE American noncompliance notice; equity $3.2M below $4M/$6M thresholds","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NYSE American notified Oragenics it fails continued listing standards due to stockholders' equity of $3.2M as of Dec 31, 2023.","Company must submit a compliance plan by May 18, 2024 to address Sections 1003(a)(ii) and 1003(a)(iii) deficiencies.","Company has until October 18, 2025 to regain compliance; stock trades as OGEN.BC during this period.","If plan is not accepted or compliance not achieved, Oragenics faces potential delisting from NYSE American."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220592,"accession_number":"0001493152-24-014704","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2024-04-16T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Oragenics sets 2023 Annual Meeting for July 15, 2024; new shareholder proposal deadline May 20","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board established July 15, 2024 as date for 2023 Annual Meeting, moved more than 30 days from 2022 meeting anniversary.","Shareholder proposals under Rule 14a-8 must be received by company by May 20, 2024.","Record date, time and location will be disclosed in the proxy statement.","Proposals to be sent to Oragenics, Inc., Attn: Corporate Secretary, 1990 Main Street, Suite 750, Sarasota, FL 34236."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240232,"accession_number":"0001493152-24-010192","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2024-03-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oragenics appoints Dr. James Kelly as CMO to lead Phase II concussion trial","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Kelly will serve as CMO under an independent contractor agreement at $400/hour for 20 hours/month.","He will oversee the Phase II trial of ONP-002, an intranasal NCE for mild traumatic brain injury.","ONP-002 completed a 40-patient Phase I safety study; a 69 million annual concussion market cited.","Dr. Kelly previously led the Marcus Institute for Brain Health and founded the NICoE at Walter Reed.","Company is completing GMP drug manufacturing for the Phase II trial initiation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240231,"accession_number":"0001493152-24-008489","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2024-03-01T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Oragenics closes $2.1M public offering of 1.4M shares; funds ONP-002 development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 1,400,000 shares at $1.50/share for gross proceeds of $2.1M.","Underwriters granted a 45-day option for up to 210,000 additional shares.","Net proceeds to fund continued development of ONP-002 for concussion treatment.","Representative's warrants issued for up to 5% of Shares at $1.875/share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2729734.3208828527,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-03-01T23:59:59+00:00|240231"}